Resveratrol inhibits tumor necrosis factor-α-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells

Biomedicine and Pharmacotherapy

Volumn 62, Issue 6, 2008, Pages 366-372

  Yu, Haibo ^a   Pan, Chengen ^a   Zhao, Sihai ^a   Wang, Zheng ^a   Zhang, Huifeng ^b   Wu, Wujun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Invasion; MMP 9; NF kappa B; Resveratrol; TNF

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYPHENOL; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; SIGNAL TRANSDUCTION; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46049093970     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.09.006     Document Type: Article

References (32)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Tang Z.Y., Ye S.L., Liu Y.K., Qin L.X., Sun H.C., Ye Q.H., et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 187-196
3. Mitsunobu M., Toyosaka A., Oriyama T., Okamoto E., and Nakao N. Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 14 (1996) 520-529
4. Vlodavsky I., and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108 (2001) 341-347
5. Adithi M., Nalini V., Kandalam M., and Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol 29 (2007) 399-405
6. Kader A.K., Liu J., Shao L., Dinney C.P., Lin J., Wang Y., et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13 (2007) 2614-2620
7. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
8. Cho K., Tajiri T., Ishiwata T., Uchida E., Aimoto T., and Nakamura Y. Keratinocyte growth factor and its receptor correlate with venous invasion via matrix metalloproteinase-9 (MMP-9) in pancreatic cancer. Pancreas 33 (2006) 452
9. Yamamoto H., Vinitketkumnuen A., Adachi Y., Taniguchi H., Hirata T., and Miyamoto N. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis 25 (2004) 2353-2366
10. Vaslamatzis Michael M., Petraki Constantina C., Papathoma A., Papanastassiou P., Mastoris C., and Alevizopoulos N. Matrix metalloproteinases MMP-2 and MMP-9 as prognostic markers in urothelial carcinoma. Ann Oncol 10 (2002) 18-22
11. Arii S., Mise M., Harada T., Furutani M., Ishigami S., and Niwano M. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24 (1996) 316-322
12. Sakamoto Y., Mafune K., Mori M., Shiraishi T., Imamura H., and Mori M. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 17 (2000) 237-243
13. Sen R., and Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 47 (1986) 921-928
14. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64 (2002) 883-888
15. Yu Y.Y., Li Q., and Zhu Z.G. NF-κB as a molecular target in adjuvant therapy of gastrointestinal carcinomas. Eur J Surg Oncol 31 (2005) 386-392
16. Shehata M., Shehata M., Shehata F., and Pater A. Dual apoptotic effect of Xrel3 c-Rel/NF-κB homolog in human cervical cancer cells. Cell Biol Int 28 (2004) 895-904
17. Fujita M., Goto K., Yoshida K., Okamura H., Morimoto H., and Kito S. Okadaic acid stimulates expression of Fas receptor and Fas ligand by activation of nuclear factor kappa-B in human oral squamous carcinoma cells. Oral Oncol 40 (2004) 199-206
18. Hou M.F., Lin S.B., Yuan S.S., Tsai S.M., Wu S.H., and Ou-Yang F. The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. Clin Chim Acta 334 (2003) 137-144
19. Liu P., Kimmoun E., Legrand A., Sauvanet A., Degott C., and Lardeux B. Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 37 (2002) 63-71
20. Luo J.L., Kamata H., and Karin M. IKK/NF-kB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115 (2005) 2625-2632
21. Philip S., Bulbule A., and Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type I matrix metalloproteinase in melanoma cells. J Biol Chem 276 (2001) 44926-44935
22. Keutgens A., Robert I., Viatour P., and Chariot A. Deregulated NF-κB activity in haematological malignancies. Biochem Pharmacol 72 (2006) 1069-1080
23. Ferguson L.R. Role of plant polyphenols in genomic stability. Mutat Res 475 (2001) 89-111
24. Middleton E.J., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000) 673-751
25. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., and Beecher C.W. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
26. Sun C., Hu Y., Liu X., Wu T., Wang Y., He W., et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165 (2006) 9-19
27. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (1999) 1237-1241
28. Chung T.W., Lee Y.C., Ko J.H., and Kim C.H. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 63 (2003) 3453-3458
29. Scorilas A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., and Trangas T. Overexpression of matrix metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84 (2001) 1488-1496
30. Bond M., Fabunmi R.P., Baker A.H., and Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett 435 (1998) 29-34
31. Li J.J., Westergaard C., Ghosh P., and Colburn N.H. Inhibitors of both nuclear factor-kappa B and activator protein-1 activation block the neoplastic transformation response. Cancer Res 57 (1997) 3569-3576
32. Meyer R., Hatada E.N., Hohmann H.P., Haiker M., Bartsch C., and Röthlisberger U. Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha. Proc Natl Acad Sci U S A 88 (1991) 966-970